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Osteoarthritis (OA) is the predominant form of arthritis worldwide, resulting in a high 
degree of functional impairment and reduced quality of life owing to chronic pain. 
To date, there are no treatments that are known to modify disease progression of OA 
in the long term. Current treatments are largely based on the modulation of pain, 
including NSAIDs, opiates and, more recently, centrally acting pharmacotherapies to 
avert pain. This review will focus on the rationale for new avenues in pain modulation, 
including inhibition with anti-NGF antibodies and centrally acting analgesics. The 
authors also consider the potential for structure modification in cartilage/bone using 
growth factors and stem cell therapies. The possible mismatch between structural 
change and pain perception will also be discussed, introducing recent techniques that 
may assist in improved patient phenotyping of pain subsets in OA. Such developments 
could help further stratify subgroups and treatments for people with OA in future.
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Osteoarthritis (OA) is the most common 
arthritic joint disorder that is typified by sig-
nificant structural joint damage, functional 
impairment and pain [1,2]. There are cur-
rently no treatments that are known to mod-
ify disease progression. At present, licensed 
treatments for OA are focused on the relief 
of pain symptoms and other physical treat-
ments aiming to improve function – that is, 
physiotherapy and rehabilitation [3]. Many 
people with OA continue to suffer from pain 
symptoms despite currently available treat-
ments [4,5]. As the incidence of OA contin-
ues to rise in an aging population worldwide, 
there remains a high unmet need to develop 
new treatments for OA that target symptom 
relief and improve patients’ quality of life [6]. 
Disability in OA arises from pain, reduced 
range of movement and diminished control 
of the affected joint. The pain and functional 
consequences of OA are responsible for the 
large burden of morbidity in the community. 
In a study by Hochberg et al., women (but 
not men) with OA of the knee had higher 
morbidity and cumulative mortality rates 
between the ages of 55–74 years [7]. Increased 
mortality has also been associated with OA of 
the knee in Sweden [8]. Although comorbidi-
ties may result in the increased mortality, it 
is important to consider the extent to which 
OA contributes to the deterioration of an 
individual’s wellbeing. To date, few disease-
modifying therapies exist for the treatment 
of OA. In comparison, inflammatory arthri-
tis, for example, rheumatoid arthritis and 
psoriatic arthritis, can often be successfully 
treated with immunomodulatory therapies, 
including methotrexate and TNF inhibitors, 
which delay disease progression [9].
This review will highlight areas of recent 
developments in our understanding of pain 
in OA. We discuss potential novel therapeu-
tic options for OA pain management, with 
an evaluation of targets for local mediators 
in the OA joint, including proinflamma-
tory molecules, neurotransmitters including 
ion channels, opioids and NGF, together 
with the modulation of cartilage/bone part of
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turnover including agents such as strontium ranelate 
and bisphosphonates. Local intra-articular therapies 
for OA could also prove to be effective in future and 
the authors will discuss the rationale for trials aimed 
at potential therapies, such as intra-articular FGF-18. 
Trials are also under way for the use of biological 
agents including mesenchymal stem cells (MSCs) in 
the treatment of cartilage defects in OA. While the OA 
novel treatment pipeline develops, recent work has also 
focused on optimizing treatment pathways for existing 
drugs, including NSAIDs, opiates and centrally-acting 
analgesics, for example, the serotonin–noradrenaline 
reuptake inhibitor duloxetine in the treatment of OA 
will also be discussed.
Pathological changes in the osteoarthritic 
joint
OA is an arthropathy of synovial joints that is char-
acterized by cartilage loss in which there is often evi-
dence of a periarticular bone response [10]. In the early 
stages of disease, cartilage develops irregularities at the 
surface where it becomes fibrillated and appears mod-
erately hypercellular [11]. As the condition progresses, 
deep clefts form in the cartilage, with loss of aggrecan 
and type II collagen within the cartilage extracellular 
matrix (Figure 1). Chondrocytes also clump within 
cartilage, surrounded by regions of intense staining 
material indicating increased proteoglycan. As ongo-
ing cartilage damage occurs, the articular joint surface 
is damaged, leading to loss of joint function. Recent 
work has shown that cartilage is not the only struc-
ture undergoing pathological change in OA, and other 
important structures in the OA joint, for example, 
bone marrow lesions (BMLs) [12] and synovitis [13] have 
an impact on pain perception and OA pathophysiol-
ogy, which will be discussed in further detail in this 
article.
Clinically, OA can be divided into a number of sub-
sets. Nodal OA is a well-recognized subset, character-
ized by polyarticular interphalangeal joint involvement 
of the fingers. There is formation of Heberden’s nodes 
(distal interphalangeal joints) and Bouchard’s nodes 
(proximal interphalangeal joints) [14]. In addition, this 
subset has a female preponderance, a peak onset in 
middle age, predisposition to OA of the hip/knee/spine 
with a marked familial predisposition. OA is a multi-
factorial disease in which genetic predisposition, age, 
estrogen status in women and environmental agents 
all contribute to susceptibility. In families with hand 
OA, a greater concordance exists for monozygotic 
twins than for dizygotic twins [15]. There is also an 
increased incidence of hand OA in first-degree rela-
tives [16]. Some studies have investigated the nature 
of the genetic abnormality in subjects with hand OA. 
Associations have been reported with single nucleotide 
polymorphisms in the human chromosome 2q that are 
linked with the IL-1 region on this chromosome [17]. 
Mutations in an extracellular matrix protein, matri-
lin-3, have also been linked with hand OA [18]. Sev-
eral studies have found links between OA and HLA 
status, including the association of HLA-B, -C, -DR 
and -DQ in two different studies involving European 
[19] and Japanese [20] cohorts. Pain severity in OA may 
also have genetic contributions. A functional polymor-
phism (Val158Met) in the COMT gene is associated 
with painful knee OA [21]. Other gene polymorphisms 
involving genes implicated in pain perception, for 
example, TRPV1, have been reported to be associated 
with painful knee OA [22]. With respect to pain sen-
sitivity, TRPV1 and the PACE4 gene Pcsk6 were asso-
ciated with pain in knee OA in two separate genetic 
association studies [23]. Recently, a large consortium 
genome-wide association studies in 7410 subjects with 
OA, the arcOGEN study, showed several significant 
loci relating to cartilage metabolism and obesity [24]. 
Results showed the most significant association was 
with the GLT8D1 gene, associated with glycosylation 
of cartilage proteins [24]. Other significant associa-
tions included the CHST11 gene, associated with the 
metabolism of cartilage proteoglycans and the FTO 
gene, which is linked to body weight and obesity. It, 
therefore, appears that some of the clinically recog-
nized risk factors for OA and mediators of cartilage 
metabolism are reflected in genetic risk signals, leading 
to the clinical syndrome of pain and reduced function 
recognized as OA.
In recent years, there has been a greater understand-
ing of how radiographic changes occurring in the OA 
joint, including osteophytes, synovitis and BMLs, 
relate to pain (Figure 2). Typical radiographic features 
observed by plain radiography, including narrowing of 
the joint space owing to loss of cartilage, osteophyte 
formation, bone sclerosis and bone cysts, can be better 
understood in the context of changes within other joint 
structures, including synovium and bone, which  are 
aided by MRI techniques [25]. However, it is still 
unclear as to which changes are most important for 
pain perception. It has been suggested that BMLs and 
synovitis have the highest correlations with pain [26,27]. 
The correlations of pain with synovitis and BMLs will 
be used as a basis for the discussion of novel therapies 
for pain in OA in the sections below.
Risk factor modification for OA
Apart from the genetic associations already described, 
the development of OA is also linked with other risk 
factors. Several studies have reported a correlation of 
obesity with an increased risk of knee OA [28–31]. A 
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Finnish group observed 823 subjects without baseline 
knee OA in which a strong correlation of incident knee 
OA with BMI was found (odds ratio: 1.75; 95% CI: 
1.0–2.8), with a higher odds ratio (odds ratio: 7.0; 
95% CI: 3.5–14.1) for the group with a greater BMI 
(BMI ≥30.0) [29]. The Framingham study also analyzed 
598 knee OA subjects who demonstrated an increased 
risk of incident knee OA with a higher baseline BMI 
(odds ratio: 1.6 per 5-unit BMI increase; 95% CI: 
1.2–2.2) [28]. The Chingford study found obesity to be 
a predictor for the development of contralateral OA in 
women with unilateral OA [32]. Such results supporting 
the risk of heavier individuals developing OA are impor-
tant to consider when discussing modifiable risk factors 
for OA [33]. Weight loss and exercise are popular inter-
ventions for OA [34]; how they influence OA progression 
and pain is further discussed in the following section.
Exercise & weight loss
In the case of exercise therapy for OA, land-based or 
water-based exercise and strength training have been 
subjected to meta-analyses. Four meta-analyses have 
found there to be small, but clinically relevant short-
term benefits of land-based exercise for pain and physical 
function in knee OA [34–37]. The duration and type of 
exercise programs included in the meta-analyses varied 
quite widely, but interventions often comprised a com-
bination of elements, which included strength training, 
active range of motion exercise and aerobic activities. 
Although results were favorable in most types of land-
based exercise, no specific exercise program appeared 
to be more favorable [34–37]. Of note, meta-analyses 
investigating t’ai chi found favorable benefits in improv-
ing pain and physical function in people with knee OA 
[38,39]. With respect to strength training, a meta-analysis 
and systematic review published in 2011 showed moder-
ate effect sizes for reducing pain and improving physical 
function compared with controls [34]. Of note, recent 
data from MOST suggested that people with knee OA 
had significant levels of knee instability, which was 
associated with fear of falling, poor balance confidence, 
activity limitations and reduced physical function [40], 
which can all have an impact on the level of physical 
activity achievable by people with OA by exercise inter-
ventions [40]. Although there are reports, particularly 
from animal models, of high physical activity worsening 
OA lesions [41], clinical studies have been less clear and 
current guidance recommends exercise for amelioration 
of pain and improved function in OA.
Recent reports have outlined the rationale for weight 
reduction in OA in recommendations from both 
EULAR [42] and OARSI [43]. In 2007, Christensen 
et al. published a meta-analysis and systematic review 
of weight management in OA [44]. The authors found 
reductions in pain and physical disability for overweight 
participants with knee OA after a moderate weight 
reduction regimen [44]. The authors reported that a 
weight loss of 5% should be achieved within a 20-week 
period, that is – 0.25% per week, for the treatment to 
have efficacy for pain relief and improved function.
Osteophytes & their effect on OA pain
Osteophytes, sometimes described as osteochondrophytes 
or chondro-osteophytes, are a classical feature of OA 
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Figure 1. Histological features of tissue damage in osteoarthritis. (A) There is abundant staining of proteoglycans 
within cartilage with chondrocytes visible within this section of normal cartilage stained with toluidine blue. 
(B) Early osteoarthritic cartilage showing loss of cartilage extracellular matrix staining, reduction in chondrocytes 
and early fibrillation of the articular surface of cartilage; stained with fast green and toluidine blue. (C) Severely 
damaged osteoarthritic cartilage showing profound loss of proteoglycans staining and fissuring of the cartilage 
articular surface. The section is stained with toluidine blue. Osteoarthritis samples (B) and (C) were obtained at 
the time of joint replacement surgery from patient with osteoarthritis. Normal cartilage was obtained from a 
donor undergoing surgery for osteosarcoma. Full informed consent was obtained for all studies.
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joint pathology (Figure 2), and are found in people with 
OA and in experimentally induced models. They can 
appear early in OA, often a precursor to joint space 
narrowing. Resulting from endochondral ossification 
at the margins and areas of cartilage loss in OA joints, 
these structures arise within tissue close to the chondro-
synovial junction from progenitor cells. Progenitors 
may include MSCs residing within the perichondrium 
and synovium [45,46], suggesting there is a reserve of 
pluripotent cells receptive to joint injury. By examin-
ing osteophytes of distinct developmental stages within 
patients, a successive pattern of differentiation can be 
seen [47]. At first progenitor cells at the osteochondral 
junction are stimulated by growth factors, such as 
TGF-β and basic FGF, to proliferate [48]. The cells 
within the chondrophyte undergo chondrogenesis and 
deposit extracellular matrix proteins, such as aggrecan 
and glycosaminoglycan. Within the early osteophyte, 
chondrocytes undergo hypertrophy followed by endo-
chondal ossification, deposition of bone and formation 
of marrow cavities. Once the mature osteophyte is fully 
formed, it will integrate with the subchondral bone and 
the original cartilage [46,49]. Osteophytes are considered 
to be an adaptive reaction of the joint to mechanical 
stress and instability. It has been suggested that they 
may provide a compensatory role to redistribute weight 
bearing forces and stabilize joints affected by malalign-
ment and OA [48,50,51]. Osteophytes are often removed 
at the time of joint replacement surgery or cheilectomy 
procedures, removing the mechanical pressure they 
apply to surrounding structures. More recent tech-
niques of unicompartmental joint replacement surgery 
targets areas that may be specifically affected by such 
lesions and, therefore, have a good impact on pain and 
joint translocation in the long term [52]. Osteophytes 
cause joint pain by stretching and compressing nerves 
future science group
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Figure 2. Radiographic features of tissue damage in osteoarthritis. (A) Example of osteophytes (white arrows) 
shown in the anterior lumbar vertebral bodies. (B) MRI with T2-weighted sequences demonstrating cartilage loss 
(white arrow) in patient with osteoarthritis. (C) MRI with T2-weighted sequences demonstrating bone marrow 
lesions localized to the knee patella (white arrow) in a patient with osteoarthritis. Image acquisition paradigm for 
MRIs courtesy of Franklyn Howe (St George’s University, London, UK).
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and compromising blood flow, possibly causing motor, 
sensory impairment and faintness, and, in worse cases, 
impact surrounding tissue and organs [45], while some 
osteophytes are asymptomatic and could form within 
healthy individuals. Reports demonstrate that antire-
sorptive drugs that prevent the formation of cancellous 
subchondral bone have no effect on the development of 
osteophytes. Similarly, no inhibition is seen with doxy-
cycline; however,  anti-inflammatory drugs, such as glu-
cocorticoids, have an anti-anabolic effect and halt osteo-
phytosis [53–55]. It is evident that the role osteophyte have 
on pain and function is dependent on their location and 
disease stage, in end stage OA of larger joints they may 
act to stabilize the degenerated joint, while osteophytes 
of the spine are often painful and debilitating [48].
BMLs & OA pain
Several studies have demonstrated the correlation of 
BMLs with pain, particularly in large joint arthritis 
[27,56]. This field has advanced owing to the develop-
ment of MRI techniques, which have optimized the 
use of such technologies in visualizing lesions at the 
bone–cartilage interface. BMLs are often described as 
diffuse areas of high-density signal in a T2-weighted, 
fat-saturated MRI or in short tau inversion recovery 
sequences (Figure 2) [57]. BML patterns on MRI have 
been described using various methods, some measured 
using a binary [58] or semiquantitative method (whole-
organ MRI score or 0-3 scale) [59,60] for the presence of 
lesions, several looking at distribution (global and focal 
cystic) [61], others based classification on lesion loca-
tion to the lateral and medial condyle [62], while some 
addressed changes in BML size based on quantitative 
measurements (maximal diameter or area of lesion) 
[63,64]. Although changes in BMLs have been analyzed 
by a number of methods and measurements, this has 
not significantly affected the general findings [65]. In a 
study of people with severe hip OA undergoing total 
hip replacement, Taljanovic et al. found that the quan-
tity of BMLs measured by MRI correlated with severity 
of pain and the number of microfractures observed by 
histology [66]. This study was relatively small since data 
were acquired on 19 patients; however, there are now 
larger clinical data sets observing the relation of BMLs 
to pain in OA [12,67,68]. The MOST study, which evalu-
ated 570 subjects, found that the severity of BMLs and 
synovitis were associated with fluctuation of frequent 
knee pain and pain severity [12]. MOST also showed 
that of the two types of structural lesions, BMLs were 
a better predictor of knee pain. In contrast, other 
groups have not been able to confirm the correlation 
of pain with BML as strongly as the MOST investiga-
tors [68], although larger BMLs have a more significant 
correlation with pain [69].
With respect to changes in BML over time, Garnero 
et al. evaluated 377 patients with painful knee OA, 
reporting that within 3 months, BML scores decreased 
in 37 and increased in 71 patients [70]. Assessing 182 
patients with OA at baseline and at 2-year follow-up, 
Kornaat et al. reported that total size of BML changed 
in 66% of patients, with change in size of individual 
lesions as 45%, new lesions appeared in 21%, and 
existing lesions completely disappeared in 10% of 
patients [71]. The authors concluded from their study 
that in OA, BMLs are part of a dynamic process and 
not a constant finding, as opposed to cartilage loss. 
BMLs are often associated with other MRI features 
in OA, including subchondral cysts [72], which are a 
well-defined area of fluid signal on MRI. Several lon-
gitudinal investigations have shown that areas of BML 
are related to subchondral cysts and that BMLs could 
be an early precystic lesion. Carrino et al. suggested 
that cysts arise from the regions of BML, and signal 
size of BML changes with cyst development [72]. While 
others reported that when BMLs and cystic lesions are 
in close proximity, the direction in which they change 
is identical [71]; however, not all BMLs will give rise 
to a cyst. Histologically, a number of pathologies are 
seen in BMLs, ranging from edema, fibrosis, osteone-
crosis, trabecular abnormalities to bony remodeling 
[73]. At present, the cause(s) for BML development 
are not certain, but several possibilities have been sug-
gested. Hunter et al. proposed that changes in BMLs 
are in part mediated by limb alignment since medial 
BMLs occurred mostly in subjects with varus-aligned 
limbs, and lateral lesions occurred in those with val-
gus-aligned limbs [74]. It has been suggested that BMLs 
develop as a result of subchondral bone ischaemia [75], 
which impairs the exchange of nutrients and oxygen 
with articular cartilage. Such pathological processes 
could reduce cartilage integrity and increase the risk 
of OA development [76–78]. Some hypothesize that 
BMLs are a result of bony microcontusions leading to 
necrosis, or increased intra-articular pressure resulting 
in the extension of synovial fluid into the subchondral 
bone and proliferation of myxomatous tissue within 
bone marrow. A similar theory suggest that BMLs may 
develop if synovial fluid is pumped into subchondral 
bone marrow through defects in articular cartilage, or 
from increased stress placed on the subchondral bone 
owing to overlaying articular cartilage loss – potentially 
resulting in subchondral microfracture and marrow 
edema [79]. Felson and colleagues demonstrated BMLs 
are more likely to be present in painful knees as opposed 
to nonpainful knees, finding large BMLs in 37% of 
patients with symptomatic radiographic OA compared 
with 2% in the asymptomatic patients (p < 0.001) [56], 
which was confirmed by Sowers et al. [68], but not by 
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Kornaat and colleagues [80]. BMLs were also strongly 
associated to cartilage loss, primarily within areas over-
lying the lesion [74]. At end stage OA, the joint harbors 
many pathological features that contribute to arthritic 
pain. Owing to this coexistence of such defects, it is 
difficult to determine which single lesion activates and 
causes pain. Investigators are currently examining how 
specific MRI changes correlate with clinical features of 
OA pain in longitudinal studies as this will be helpful 
in considering avenues for novel therapies [81].
With respect to therapeutic interventions aimed 
at modulation of BML, recent work has focused on 
potential use of drug interventions that have previously 
been utilized to modulate bone density, for example, 
bisphosphonate drugs. Bisphosphonates are a class of 
drugs that inhibit osteoclast bone resorption. A recent 
meta-analysis by our group evaluating studies involv-
ing 3832 patients with OA of the hand, hip, knee and 
spine found that, overall, bisphosphonates showed 
limited efficacy in analgesia for OA [82]. However, a 
few studies did show benefit with specific drugs in the 
class. In the two largest studies that tested the effects 
of risedronate in knee OA [83,84], our meta-analysis 
showed no statistically significant difference in pain or 
functional outcomes assessed by Western Ontario and 
McMaster Universities OA Index (WOMAC) with 
risedronate over placebo arms at doses of 5 mg daily, 
or 15, 35 and 50 mg weekly. The remaining studies, 
which could not be evaluated by meta-analysis, showed 
that bisphosphonates reduce pain greater than placebo 
or nonreatment controls in OA in Asian, European and 
North American populations when assessed by visual 
analog scale and WOMAC outcomes. There was het-
erogeneity across the studies analyzed, with variability 
in anatomical position of disease, gender studied, route 
and frequency of drug administration. Specifically, 
zoledronate has been used in intravenous formulation 
in a trial of patients with knee OA. Laslett et al. com-
pared clinical outcomes between a single infusion of 
zoledronate (5 mg/100 ml) to a placebo control group 
[85]. This trial showed significant improvements in 
pain using the visual analog scale at 6 months, which 
was the primary end  point of this study. The authors 
also reported a reduction in total BML area of greater 
magnitude in the zoledronate group compared with 
placebo after 6 months (-175.7 mm2; 95% CI: -327.2 
to -24.3) with a nonstatistically significant trend after 
12 months (-146.5 mm2; 95% CI: -307.5–14.5). With 
respect to adverse events, the most common was cold 
or flu symptoms, which was 78% of the 90% total [85]. 
In other reports, a flare-up of OA pain and inflamma-
tion has also been described with zoledronic acid infu-
sion [86]. It is, therefore, possible that drugs targeting 
bone turnover may be increasingly considered for 
modulating processes targeting bone turnover in OA; 
however, further work is required in this area. In more 
recent work from Nishii et al., 50 participants with 
symptomatic hip OA were randomized to treatment 
with alendronate (35 mg/week and 600 mg/day cal-
cium lactate) or a control group (600 mg/day calcium 
lactate) for 2 years [87]. Alendronate treatment by stan-
dard dose for osteoporosis showed clinical efficacy for 
decreasing pain, but failed to show preventative effects 
for structural progression of hip OA. Recent data 
reported from the NIH OA Initiative cohort of sub-
jects with knee OA investigated changes in pain scores 
in participants taking bisphosphonate therapy [85]. The 
study reported significant reduction in numeric rating 
pain within the first 3 years of bisphosphonate use, 
with reduction in effects by year 4, possibly owing to 
reduced compliance. A sample size of 55 patients who 
were bisphosphonate users was studied and, therefore, 
larger studies would be useful for further evaluation of 
therapeutic effects.
Recently, a clinical trial has also been published on 
the use of another bone modulator: strontium ranelate 
in the treatment of OA [88]. Strontium ranelate is 
already licensed for use in osteoporosis. Strontium 
ranelate is a strontium (II) salt of ranelic acid and is 
known to increase deposition of new bone by osteo-
blasts and reduce bone resorption by osteoclasts. A 
recent double-blind, randomized, placebo-controlled 
trial, investigated its potential efficacy in OA pain. 
Reginster et al. reported outcomes for patients who 
had moderate OA of the knee, with Kellgren and Law-
rence grade 2/3 and joint space width of 2.5-5 mm [88]. 
Patients were randomized to either strontium ranelate 
1 g/day (n = 558), 2 g/day (n = 566) or placebo (n 
= 559). This study reported that the rate of disease 
progression measured by joint space narrowing was 
reduced in the strontium ranelate group at 1 or 2 g 
daily compared with placebo. The study group also 
reported greater reduction in WOMAC pain subscore 
(p = 0.028) and knee pain (p = 0.065) with strontium 
ranelate 2 g/day after 3 years of treatment. A more 
recent analysis of the use of strontium ranelate in the 
same study showed disease-modifying effect of stron-
tium ranelate in a subset of patients from the Phase 
III knee OA study SEKOIA using quantitative MRI 
[89]. The authors showed a reduction in BMLs protects 
against cartilage loss.
In the future, it remains to be seen whether the tol-
erability of an agent, such as strontium ranelate, would 
be sustained for more than 5 years, and if taking such 
a drug for a certain period of term confers chondro-
protection and pain relief or whether indefinite use is 
required. It should also be recognized that patients at 
risk of developing deep vein thrombosis and myocardial 
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Figure 3. Molecular mechanisms of pain in osteoarthritis (see facing page). (A) Left: normal joint structure; 
right: changes taking place in the synovial joint during the development of OA. (B) Bone cells (osteoblasts. 
osteoclasts and osteocytes), fibroblasts, macrophages and mast cells from the SCB invade the CC and the 
NCC, via microfractures in the bone–cartilage interface. The disruption of the osteochondral junction 
promotes production of enzymes, growth factors and molecules (ADAMTS-4, ADAMTS-5, AGEs, BMPs, FGF-18, 
MMP-3, MMP-13, NGF, TGF-β and VEGF) by the invading cells and chondrocytes stimulating innervation and 
vascularization ultimately recruiting NVBs (BV and PNF) from the HC. (C) Inflammation in the synovium or 
synovitis causes joint swelling and effusion. Hyperplasia is seen in the synovial tissue resulting in the formation 
of a HSL followed by the infiltration of inflammatory cells – possibly owing to a systemic response or secondary 
to cartilage degradation or bone marrow lesion formation. Factors, enzymes and cytokines (GM-CSF, IL-1 family, 
IL-6 family, MMPs, NGF, TNF-α, and VEGF) stimulated via the cells encourage innervation and angiogenesis (NVB: 
BV and PNF). (D) Peripheral inflammation, cartilage degradation and bone marrow lesions produce numerous 
inflammatory mediators (e.g., sensitisers: bradykinin, a peptide which causes blood vessels to dilate; E2 stimulates 
osteoblasts to release factors that stimulate bone resorption by osteoclasts; PGE2; substance P, a neuropeptide 
belonging to tachykinin neuropeptide family; and TNFR-α) and growth factors (e.g., GDNF and NGF) activating 
their subsequent receptors (bradykinin receptor B2, EP2, GDNF-α, NK1, TNFR1 and TRKA). The sensitizers work 
by phosphorylating TRPs: TRPA1 and TRPV1, facilitating the trafficking of the channels to the membrane of the 
PT. Once in the membrane of the PT, TRPA1 modulates calcium exchange with TRPV1 enhancing the nociceptive 
activity of both channels. The growth factors are transported down the neuron towards the DRG. Altered 
sensitization of such signaling pathways decreases the pain threshold in OA patients (RPT). (E) During ST, growth 
factors (GDNF and NGF) are transmitted into the cell body of the DRG, where they facilitate intracellular signaling 
pathways, for example, the MAPK cascade upregulating the expression of TRP channels (TRPA1/TRPV1), which are 
then transported via the neuron into the PNF and PT. Changes in this pathway during OA can switch the activity 
of the neurons to an altered state encouraging peripheral sensitization and RPT at the impaired site. Signaling 
pathways activated in the DRG then take effect in central processes. 
AGE: Advanced glycation end product; BMP: Bone morphogenetic protein; BV: Blood vessel; CC: Calcified 
cartilage; DRG: Dorsal root ganglion; EP2: Prostaglandin E2 receptor; GM-CSF: Granulocyte macrophage 
colony-stimulating factor; HC: Haversian canal; HSL: hyperplastic synovial lining; MMP: Matrix metalloproteinase;  
NCC: Noncalcified cartilage; NVB: Neurovascular bundle; OA: Osteoarthritis; P: Phosphorylation;  
PGE2: Prostaglandin E2; PNF: Perivascular nerve fiber; PT: Peripheral terminal; RPT: Reducing the pain threshold;  
SCB: Subchondral bone; ST: Signal transduction; TRP: Transient receptor potential cation channel. 
Image courtesy of Gayanthi Perera.
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infarction cannot be prescribed strontium ranelate, 
suggesting that such an agent would require careful 
screening and monitoring in the OA population.
Further studies have recently been published report-
ing the use of specific pharmacological agents to target 
OA pain. These include a study by Esenyel et al. in 
which nasal calcitonin was assessed for the treatment 
of knee OA [90]. This study of 220 postmenopausal 
women demonstrated a significant improvement in 
pain (p < 0.001), stiffness (p < 0.05) and functional 
level (p < 0.05) after 1 year of treatment. Other emerg-
ing studies, albeit in animal models so far,  suggested 
that inhibition of specific proteases, for example, 
cathepsin K, could be beneficial in OA treatment. 
For example, Hayami and colleagues reported that a 
cathepsin K inhibitor was able to reduce cartilage deg-
radation and osteophyte formation in a rabbit model of 
OA [91]. Cathepsin K inhibition has also been shown 
to reduce type II collagen degradation in a guinea pig 
model of OA [92]. Other agents such as parathyroid 
hormone have also been shown to improve the struc-
ture of articular cartilage, but the effect of parathyroid 
hormone on pain in OA is as yet unknown [93].
Targeting synovitis to treat OA pain
Synovitis is a process characterised by inflamma-
tion. It is increasingly recognized that synovitis is a 
key factor associated with the signs and symptoms of 
OA, including joint swelling, stiffness and pain [94], 
which all indicate the presence of synovitis due to a 
thickened synovium or effusion. Synovitis, which 
involves the penetration of mononuclear cells into the 
synovial membrane and the production of prinflam-
matory cytokines, such as IL-1, IL-6, TNF-α and 
granulocyte macrophage colony-stimulating factor are 
upregulated in OA tissue (Figure 3) [95]. There is also 
increased expression of VEGF and matrix metallopro-
teinase (MMP) expression in OA synovial tissue, but at 
significantly lower levels than in patients [94].
Gadolinium-enhanced MRI and ultrasonography 
are useful and convincing tools for the observation of 
synovitis [96]. Studies using such methods of imaging 
suggest that the presence of synovitis may be a marker 
for the severity and increased risk of the radiographic 
progression of OA. Systemic high-sensitivity C-reac-
tive protein levels have been reported to mirror syno-
vial inflammation in OA patients and correlate with 
increased pain [97]. How and why the synovium 
becomes inflamed during the development of OA has 
been investigated. One hypothesis is that degraded 
cartilage fragments, such as advanced glycation end 
products, contact the synovium: these fragments are 
recognized as foreign bodies and prompt the synovial 
cells to produce inflammatory mediators from within 
the synovium and adjacent cartilage (Figure 3). These 
mediators are suggested to activate chondrocytes pres-
ent in the superficial of the cartilage, leading to MMP 
synthesis and perpetuating cartilage degradation. 
Such inflammatory mediators may also be involved 
with synovial angiogenesis and could increase the 
synthesis of inflammatory cytokines and MMPs by 
the synovial cells themselves, initiating an irreversible 
positive feedback cycle [98]. Another theory proposes 
synovial tissue to be a primary trigger in OA, along 
with many other cell types involved in many immu-
nological processes have been linked to the initiation 
and progression of OA [99]. Recently the importance of 
synovial gene expression to global joint pathology has 
been supported by the abundance of the synovial fluid 
proteome with distinct profiles found in healthy indi-
viduals compared with early OA in people undergoing 
arthroscopy after injury of the medial meniscus and 
late-stage patients undergoing joint replacement [100]. 
Other findings have also suggested a central role for 
complement in low-grade inflammation in OA. Pro-
teomic and transcriptomic analyses of synovial fluid 
and synovial tissue from individuals with OA showed 
expression and activation of complement in human 
OA joints [101]. Authors showed that mice genetically 
deficient in complement component 5 (C5), C6 or the 
complement regulatory protein CD59a did not develop 
OA in comparison to their wild-type counterparts in 
three distinct animal models of OA. The expression 
of the matrix degrading enzyme MMP-13 colocalized 
with the complement complex in chondrocytes around 
osteoarthritic cartilage. It is, therefore, conceivable 
that molecules targeted to such areas may be of use 
in the inhibition of cartilage injury in the initial steps 
during the development of OA.
Synovitis has been targeted with both intra-articular 
and systemic corticosteroid treatment in previous trials 
with good effect (Figure 3) [102]. However, the effects 
of such agents do not appear to be sustained over time. 
This has led to several researchers calling for the poten-
tial need for use of conventional disease-modifying 
drugs in OA, including methotrexate [103] and 
hydroxychloroquine [104]. It is interesting to note that 
corticosteroids in the form of low-dose prednisolone 
were not shown to be effective in a clinical trial of 
hand OA [105]. It could therefore be argued that in OA, 
where low-dose oral corticosteroids are not efficacious, 
the potential mechanism of disease-modifying anti-
rheumatic drugs such as methotrexate and hydroxy-
chloroquine, may be targeted at other compartments 
apart from synovium, for example, cartilage or bone.
Other groups have argued that more targeted thera-
pies, for example, towards MMP, may be considered. 
In the largest study of its kind using doxycycline, 
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which inhibits MMP activity, placebo was compared 
with doxycycline in women with unilateral knee OA 
[106]. The trial involved treatment with doxycycline 
100 mg twice daily in the treatment arm versus pla-
cebo, also given twice daily. A total of 431 patients 
were recruited and showed that after 30 months treat-
ment, doxycycline slowed the rate of joint space nar-
rowing in affected knees. Of interest, drug intake had 
no effect on joint space narrowing in the contralateral 
knee, suggesting other factors may also be at play. A 
recent meta-analysis that included a more recent study 
showed that doxycycline conferred no overall benefit 
in pain, with a minimal improvement in joint space 
narrowing that was outweighed by poor tolerability of 
the drug owing to side effects [107].
NSAIDs & nutraceuticals treatment
Traditionally, proinflammatory mediators have been 
targets for the inhibition of inflammation and conse-
quently pain (Figure 3). NSAIDs inhibit the COX path-
way, thereby inhibiting action of prostaglandins and 
leukotrienes in the OA joint. They are recommended 
as the first line of treatment for moderate-to-severe OA, 
used by 20–30% sufferers [108,109], despite the number 
of individuals who die from NSAID toxicity every year 
[110,111]. NSAIDs have been one of the most frequently 
used drugs for over 30 years with 80% of rheumatolo-
gists prescribing NSAIDs for symptomatic OA [112–114]. 
More recently, the second-generation COX-2 inhibitors 
(rofecoxib, etoricoxib and lumiracoxib) were favored 
as a safer alternative with superior specificity and effi-
cacy reducing the number of adverse events. However, 
it was not long before these were also associated with 
a higher risk of cardiovascular- and gastrointestinal-
related adverse events [115,116]. Ultimately, in 2007, the 
US FDA issued a medication guide for NSAIDs recom-
mending physicians to prescribe the lowest dose for the 
shortest time possible [117].
Some of the landmark studies of COX-2 inhibitors 
were conducted in patients with large joint OA; which is 
especially painful and debilitating [118]. Compared head-
to-head, celecoxib and etoricoxib are equally effective in 
improving pain responses in subjects with hip or knee 
OA [119]. One of the major issues regarding prescription 
of NSAIDs is that the population group with OA are 
often older and may have other significant comorbid-
ity including cardiovascular disease. A meta-analysis of 
the MEDAL study found that etoricoxib was associated 
with a higher incidence of hypertension in compari-
son with diclofenac in people with arthritis [119]. The 
same meta-analysis suggested that treatment of hyper-
tension with calcium-channel blockers and concurrent 
NSAID use afforded better control of blood pressure in 
comparison with other antihypertensive agents assessed.
While NSAIDs provide a short-term relief for OA 
pain, it is important to consider the long-term effects 
of anti-inflammatory treatment for a condition pri-
marily initiated by articular cartilage degeneration 
that can be associated with synovitis. It has been ques-
tioned whether there a correlation between the sudden 
increase in OA: with replacement surgeries between 
1997 and 2005 significantly rising: knee replacement’s 
climbing by 69%, hip replacements by 32% and spinal 
fusion surgeries increasing by 73% [120], and the wide-
spread use of NSAIDs over the last 30 years. It is also 
possible that extensive use of NSAIDs and the increase 
in OA is probably mainly owing to the growing num-
ber of elderly and obese individuals. The LINK study 
tested the effect of indomethacin and tiaprofenic to 
placebo on radiographic progression of OA in 812 
patients [121]. After 1 year of treatment on 376 patients 
the indomethacin group showed 47% progression of 
radiographic modifications of OA, while placebo dem-
onstrated only 22%. When comparing this to the 
tiaprofenic acid group where radiographic progression 
of OA was similar in both the treatment and placebo 
group (43 and 34%, respectively), it was concluded 
that indomethacin accelerated structural damage in 
OA and this branch of the study was terminated [121]. 
The majority of reports of NSAID efficacy and toler-
ability suggests that they do have efficacy for OA pain, 
particularly in the knee [122,123], but that dosing should 
be titrated to relative comorbidity and tolerability, with 
use being focused at times of flare or high symptom 
severity. At present, guidelines favor the use of topi-
cal versus oral NSAIDs if they are efficacious, or oral 
NSAIDs in severe symptomatic disease for as short a 
duration as possible [124].
In the quest for novel therapeutic targets for OA 
pain, several studies in recent years have aimed to 
compare newer agents to existing therapies for pain. 
The GAIT trial compared the nutraceuticals glucos-
amine 1500 mg daily, chondroitin sulphate 1200 mg 
daily, celecoxib 200 mg daily or placebo in a large 
randomized trial over 24 weeks [125]. The most rapid 
response to pain relief was achieved by the celecoxib 
group, in which the highest number of patients 
achieved a 20% reduction in the summed score for the 
pain subscale of the WOMAC index [125]. Although 
the glucosamine and chondroitin sulfate groups did 
not achieve superior analgesic relief compared with the 
celecoxib group in this study of people with knee OA, 
more recent work has suggested that the nutraceuticals 
may be of benefit for analgesic relief in a subgroup of 
patients [126]. Reginster et al. also showed improve-
ment in joint space narrowing in people with knee 
OA treated with glucosamine [127,128]. However, with 
respect to disease modification, a systematic review has 
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found no statistically significant differences in mini-
mum joint space narrowing between glucosamine and 
placebo at 1-year follow-up, although a moderate effect 
was detected at 3 years [129]. Similarly, in the case of 
chondroitin, four systematic reviews have examined the 
efficacy of chondroitin for knee OA [129–132]. Results 
have varied regarding symptom relief, with some 
reviews finding no significant benefit of chondroitin 
over placebo and others finding large effect sizes in 
favor of chondroitin. Results have also been mixed 
regarding disease modification, with only some studies 
showing statistically significant decreases in joint space 
narrowing over a longer 2-year follow-up  [129,132].
Other agents targeting glycosaminoglycans turn-
over in the joint include hyaluronic acid derivatives 
[133–135]. Hyaluronan is a normal constituent of the 
synovial joint synthesized by chondrocytes in car-
tilage and also present in the synovial fluid. It serves 
to create high viscosity in synovial fluid and buffers 
fluid loss from joints. A number of formulations have 
been subjected to clinical trials, including hylan and 
hyaluronic acid derivatives [133–135]. Most of the tri-
als have been conducted in subjects with painful knee 
OA. The usual protocol for most of these studies has 
been repeated injections of hyaluronic acid, for exam-
ple, series of three injections at weekly intervals. The 
primary outcome measures included assessment of 
pain by WOMAC scores. Juni et al. showed improve-
ment in pain scores in subjects receiving three differ-
ent forms of hyaluronan [133]. Of note there, were more 
adverse effects in the hyaluronan derived from avian 
sources in comparison with bacterial sources. In this 
non-industry conducted study, a therapeutic response 
to pain was maintained even at 6 months. More recent 
studies have included control arms, for example, hyal-
uronic acid was superior to saline injection [134] but less 
effective to corticosteroid injection in the knee [135]. 
Although a number of studies have described efficacy 
of hyaluronic acid for pain, especially in knee OA, as 
outlined above, a recent meta-analysis by Bannuru 
et al. reported no superiority of hyaluronic acid over 
treatment with NSAIDs [136]. The authors of the meta-
analysis did suggest that hyaluronic acid formulations 
may have some advantages over NSAIDs with respect 
to safety [136].
NGF monoclonal antibodies
Since there is a significant side-effect profile associ-
ated with long-term use of NSAIDs and opiate anal-
gesics, recent interest in novel pain targets has grown. 
There has been a focus on NGF as a therapeutic tar-
get for pain. In contrast to TNF, NGF acts primarily 
through a direct action on sensory neurons to induce 
hyperalgesia. NGF injection into animals leads to 
prolonged hyperalgesia and allodynia [137]. Increased 
NGF production has been observed in rheumatoid 
arthritis and OA synovial cells and chondrocytes [138]. 
The first clinical trial of a humanized monoclonocal 
antibody to NGF that binds to and inhibits NGF was 
published in 2010. In this study, Lane and colleagues 
reported that 450 patients with knee OA who were ran-
domly assigned to treatment with anti-NGF antibody 
at 10, 25, 50, 100 and 200 μg/kg bodyweight achieved 
impressive reductions in walking pain scores measured 
using the WOMAC index, with a mean of 45–62% 
reduction with varying doses of tanezumab compared 
with a placebo response of 22% (p < 0.001) [139]. How-
ever, a major concern over this trial was the observa-
tion of rapidly progressive OA in a subgroup of such 
patients and hence the halting of some ongoing trials 
due to this concern at that time [140]. It has been sug-
gested that the very successful inhibition of the NGF 
target in some patients could have led to rapidly pro-
gressive OA in such cases, and further analysis of this 
data set is being carried out [141]. Trials of anti-NGF 
have now resumed and are in progress, for example, 
tanezumab and fulranumab. More recent studies have 
also been published to assess the effect of tanezumab in 
combination with NSAIDs [142] and opioid analgesics 
[143]. It will, therefore, be interesting to note whether, 
in a subgroup of patients, particularly those who are 
not taking NSAID drugs, that anti-NGF inhibition 
may be a validated therapeutic target in OA.
Growth factors & stem cell therapy
During development biosynthesis is stimulated by a 
variety of anabolic cytokines and growth factors, such 
as TGF-β, bone morphogenetic proteins and FGF. In 
OA, many factors, such as inflammatory cytokines 
TNF-α and IL-1, are produced by the synovium and 
the chondrocytes. In normal adult cartilage, chon-
drocytes synthesize matrix components very slowly 
and there is strict regulation of matrix turnover: a 
delicate balance between synthesis and degrada-
tion. In OA, however, this balance is disturbed, with 
both degradation and synthesis usually enhanced 
until changes in both bone cells and chondrocytes 
favor catabolic activity: proinflammatory cytokines, 
including IL-1, TNF-α and IL-6, act to increase the 
synthesis of MMPs, decrease MMP enzyme inhibi-
tors and decrease extracellular matrix synthesis. The 
initiation of such degradative alterations in the joint 
leads to the depletion of cell reservoirs, loss of the 
condrogenic potential of cartilage bringing about 
the preponderance of a fibrogenic phenotype and the 
structural and functional failure of the joint [144]. 
Current treatments for cartilage defects in early OA 
include surgical interventions (microfracture and 
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osteochondral auto/allo-grafts), which have shown 
promise in clinical trials [145].
Such catabolic changes may have the potential to be 
reversed by the use of a pool of growth factors [146]. The 
FGF family of growth factors regulates branching 
morphogenesis and limb development [147]. FGF-18 is 
thought to have an anabolic effect on cartilage, leading 
to increased deposition of FGF-18 in the ribs, trachea, 
spine and joints. Preclinical data of the anabolic effects 
of FGF-18 is now being followed-up by Merck Serono 
in Phase I clinical trials [147]. Investigators are currently 
looking into the therapeutic potential of endogenous 
plasma rich in growth factors that may have the poten-
tial to modulate gene expression of chondrocytes, syn-
oviocytes, macrophages and MSCs. Therapies involv-
ing the utilization of growth factors could have the 
possibility to stimulate an anabolic microenvironment 
within an affected joint. A possible approach to main-
taining the homeostasis of damaged OA joint tissue 
could be the use of growth factors, which in turn could 
improve cartilage/bone dysregulation and lead to 
reduced pain and improved function [146,148]. Platelet-
derived elements, such as platelet-rich plasma, human 
platelet lysate and platelet supernatants, are carriers of 
endogenous morphogens, which can be stimulated by 
endogenous or exogenous activators to modulate cell 
fate, encouraging cell proliferation and matrix synthe-
sis, alongside anti-inflammatory effects owing to the 
downregulation of catabolic pathways [148,149]. Platelet-
derived elements are convenient and easy to extract, 
with a high-speed recovery potential offering multiple 
growth factors at an affordable cost [149]. Platelet-rich 
plasma injections have had beneficial effects in the 
treatment of mild-to-moderate OA in approximately 
6 months compared with hyaluronic acid and neutral 
saline injections [148]. Experimental, preclinical and 
clinical studies are being reported suggesting short-
term (1–2 years) improvement, but long-term results 
on cartilage injuries and joint pain are unknown [149].
MSCs are multipotent precursors of connective tis-
sue cells that can be isolated from a wide variety of adult 
human tissues, including synovial joints. Endogenous 
MSCs could possibly act as reservoirs for cell repair or 
immunomodulatory sentinels reducing inflammation 
[144]. Current methods rely on the paracrine proper-
ties of MSCs that release several growth factors, such 
as HGF, IGF and TGF, along with anti-inflammatory 
factors, including cytokines, IL-1ra, indoleamine 2, 
3-dioxygenase and HLA antigen-G5 [150]. Chondro-
cyte and osteoblast phenotypes are established via the 
activation of pathways induced by paracrine factors, 
such as the SMAD cascade by BMP-2, TGF-3 or Wnt 
signaling [151]. Thus, the paracrine factors delivered 
by the MSCs may be more important for MSC 
therapeutic potency than stimulating repair responses 
for the differentiation of cells [144].
Early exploratory research studies used MSC-derived 
chondrocytes to regenerate cartilage in OA. A hydrated 
collagen matrix covered with MSCs was implanted into 
the joint; cartilage regeneration was complete after 6 
months, although 20–100% of the new tissue had not 
integrated into the original cartilage [151,152]. Interven-
tion with local delivery of ex vivo cultures of MSCs, as 
the chondrogenic potential of adult chondrocytes are 
lost and regression into a fibrotic phenotype initiates, 
in preclinical models of joint disease has led to promis-
ing outcomes and is now being tested in clinical trials 
recently started in 2013 [144]. Several early-stage clinical 
trials testing the delivery of MSCs via intra-articular 
injection into the knee are underway; however, the 
optimal dose and vehicle are still being optimized [144]. 
Bader and Macchiarini recently demonstrated the uses 
of stem cell techniques in several pioneering transplant 
surgeries, seeding an inert tracheal scaffold with either 
patient or donor bone marrow MSCs [153]. Further work 
is needed to characterize factors that could avert MSC 
derived chondrocyte to undergo premature hypertophy 
and understand what facilitates terminal development 
pathways for stable hyaline cartilage regeneration [154]. 
In the case of both anabolic agents, such as FGF-18, 
and stem cell therapy trials currently underway, it will 
be interesting to observe if therapies targeted at regen-
eration of damaged cartilage in people with OA will 
translate into improved outcomes for pain and function 
in the medium to long term.
Pain sensitization in OA
In chronic arthritis, a complex set of activation sig-
nals lead to the persistence of nociceptive pain. These 
include known molecular mediators of pain, such as 
substance P, prostaglandin E2, NGF, TNFR-α, bra-
dykinin, GDNF and TRPV1 (Figure 3). Recent work 
has focused on tools to measure pain peripherally and 
centrally in people with OA (Figure 4). Several groups, 
including work in our unit, have reported the use of 
quantitative sensory testing in people with OA [155–158]. 
Pain threshold testing using algometers has become 
more widely accepted for measuring pain perception 
objectively since it is reproducible over time and has 
been validated in large studies with knee OA [159] or 
intra-oral pain [160]. We have found quantitative sensory 
testing to be a useful objective measure of hand OA pain 
[158] where people with hand OA showed evidence of 
peripheral sensitisation. A recent meta-analysis of pain 
pressure threshold testing in OA showed that pain pres-
sure thresholds demonstrated good ability to differenti-
ate between people with OA and healthy controls [156]. 
Lower pain pressure thresholds in people with OA in 
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affected sites may suggest peripheral, and in remote sites 
central, sensitization. Recent studies have also shown 
that certain patients with OA may remain sensitized to 
pain even after joint replacement surgery [161].
Brain neuroimaging tools have also been used to 
investigate sensitization in OA. Gwilym et al. reported 
increased activation of brain pain processing centers 
with functional MRI in chronic hip OA, including 
the thalamus, anterior cingulate and insular cortex, 
upon quantitative sensory testing [162]. Kulkarni et al. 
reported similar activation using fludeoxyglucose 
PET in knee OA, suggesting activation of distinct 
brain regions in patients with chronic arthritic pain 
[163]. Several authors have described the phenomenon 
of chronic pain center activation during arthritis as 
central sensitization, a process thought to derive from 
hypersensitivity to stimuli by long-term activation 
of peripheral receptors in arthritic joints. A study by 
our group in people with hand OA showed significant 
activation in the thalamus, cingulate and insular 
cortex but not controls [164]. Of interest, the cingulate 
cortex is involved in developing emotion formation, 
learning and memory, suggesting that people with OA 
are adapting their responses to sensory cues in their 
hand and developing unique pain activation systems 
compared with controls. Others have suggested that 
the cingulate cortex is important in mediating affec-
tive processing of pain [165]. With increasing informa-
tion regarding sensitization in OA, recent trials have 
reported the use of centrally acting agents, such as 
the selective serotonin and noradrenaline reuptake 
inhibitor duloxetine in the treatment of OA [166]. In a 
recent review, Brown and Boulay discuss the evidence 
for the efficacy of duloxetine use in four chronic pain 
conditions including OA [167]. They report that the 
studies published so far demonstrate a superior anal-
gesic effect of duloxetine compared with placebo that 
is sustained with continued use and is also safe and 
effective when used concomitantly with NSAIDs. 
Further information on the cost utility of duloxetine 
has shown that it would be cost effective when evalu-
ated in a US population and could be particularly use-
ful in the over 65-year age group when NSAIDs have 
been prohibitive owing to side effects [168]. Other work 
by Micca et al. has shown that duloxetine is safe in 
younger and older people with knee OA [169]. Analge-
sics, such as duloxetine, may have an important role 
to play as pain-relieving options in patients who are 
unable to tolerate other classes of drugs or have dem-
onstrated lack to efficacy in response to, for example, 
NSAIDs and/or opiate drugs.
Findings from several large international studies 
suggest that the correlation between pain and struc-
tural change may not be a linear, particularly in a 
chronic disease, such as OA, when flares may occur 
(Figure 5). Emerging studies suggest that newer tech-
niques such as quantitative sensory testing and brain 
neuroimaging may help to further phenotype pain 
subgroups in OA, which could help to develop path-
ways for the treatment of OA pain in the future. If it is 
accepted that pain sensitization is influenced by both 
physical factors occurring in the joint and psychologi-
cal influences on pain, then it could be argued that an 
early combined approach of both pharmacotherapy 
plus other interventions, such as pain management 
programs, to inhibit the development of sensitization, 
for example, before chronic pain develops, could have 
an effect on clinical pain. Such interventions, early in 
the disease process, may be effective in modulating 
the development of chronic pain in OA, but will need 
to be tested in the context of clinical trials.
Conclusion
OA is a heterogeneous and debilitating disor-
der for which there are no universally accepted 
disease-modifying treatments. It affects large weight-
bearing joints including the hip and knee but also 
smaller joints often in a nodal distribution in the 
hands. Recognized risk factors include obesity, genetic 
risk and previous mechanical injury. Since OA is a 
chronic disease that often progresses after the third 
or fourth decades, any intervention for pain that is 
used needs to be safe, with minimal side effects and of 
long-term benefit. It is interesting to note that many 
of the agents discussed in this review that could have 
a therapeutic effect, are also associated with potential 
harmful effects. For example, NSAIDs, such as 
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Figure 4. Sensitisation in osteoarthritis. Summary 
of types of studies that have provided information 
regarding evidence for features of sensitization 
in osteoarthritis from brain neuroimaging and 
quantitative sensory testing studies. 
BOLD: Blood–oxygen level dependent.
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indomethacin, can lead to destruction of cartilage, as 
can treatment with anti-NGF and corticosteroid ther-
apy, suggesting that a positive effect on joint pain may 
also be associated with accelerated joint destruction, 
which is an extremely important factor in a chronic, 
long-term condition such as OA. Recent work high-
lighted in this review also suggests that the relation 
between pain and structural damage does not always 
follow a linear pattern in OA (Figure 5). Recent focus 
has been on optimizing efficacy of analgesics includ-
ing NSAIDs and opiates. Emerging data from meta-
analyses suggests a limited role for nutraceuticals 
including glucosamine and chondroitin. The physi-
cian looking after OA patients may need to consider 
the use of centrally acting analgesics, such as dulox-
etine, if there is lack of efficacy with NSAID/opiates 
over time and possibly clinical evidence of sensitiza-
tion. It is only when risk factor reduction, lifestyle 
advice and pharmacological intervention have been 
unsuccessful that joint replacement surgery can be 
considered primarily for OA of the hip and knee.
Future perspective
Compared with other inf lammatory rheumatic dis-
eases, for example, rheumatoid arthritis, there are 
no disease-modifying treatments for OA. Prom-
ising new avenues for understanding the patho-
physiology of pain include recognition of NGF 
as a potential therapeutic target in certain groups 
with OA, in addition to structure modifying agents 
including growth factors, such as FGF-18, or stem 
cell therapies, which are currently in early clinical 
trials.
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Figure 5. Complex nature of pain in osteoarthritis. Graph demonstrating potential contributing factors to 
OA pain. The multiple trajectories are shown to highlight that the relation between cartilage degradation, 
osteophytes, synovitis, bone marrow lesions, osteochondral cysts, muscle/ligament damage, psychosocial factors 
and comorbidity do not always appear to be linearly correlated from emerging studies. 
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Executive summary
Pathological changes in the osteoarthritic joint
•	 Osteoarthritis (OA)  is the most common form of arthritis affecting the whole joint, including bone, cartilage 
and synovium.
Risk factor modification for OA
•	 Exercise and weight loss have proven efficacy for OA pain.
Osteophytes & their effect on OA pain
•	 Recent work has helped our understanding of how osteophytes form and how they can bring about pain.
Influence of bone marrow lesions on OA pain
•	  Larger bone marrow lesions detected on MRI scan correlate with higher OA pain levels, especially in the knee.
•	 Emerging data is suggesting that structure modifying agents such as zoledronic acid and strontium ranelate 
could have a disease-modifying effect in OA and improve pain. 
Targeting synovitis to treat OA pain
•	 Synovitis is often observed by imaging OA joints and correlates with pain.
NSAIDs & nutraceuticals for treating OA pain
•	 NSAIDs have proven efficacy to treat OA pain. The main issues with NSAID use are reduced tolerability over 
time owing to side effects. In large meta-analyses, nutraceuticals do not show significant benefit for pain or 
structure modification.
NGF monoclonal antibodies
•	 Clinical trials targeting molecular mediators of pain, such as anti-NGF, are in progress. Recent published trials, 
for example, tanezumab in OA, were halted owing to rapidly progressing OA in a subset of patients.
Growth factors & stem cell therapy
•	 Cartilage degradation is the hallmark of OA disease and is observed to progress with worsening symptoms. 
Therapeutic options aimed at regenerating cartilage using growth factors including FGF-18, platelet-rich 
plasma and mesenchymal stem cells are currently underway.
Pain sensitization in OA
•	 Specific subgroups of people with OA show evidence of pain sensitization and future therapeutic avenues 
could be aimed at modulating this element of OA pain.
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